Lipoprotein a: An emerging risk identifier and evolving clinical target

Tsarouhas, Konstantinos; Hoursalas*, Athanasios; Vardavas, Alexander; Tsitsimpikou, Christina

doi:10.18332/pht/145601

Cited by 2 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From a pathogenic perspective, the results are also consistent with those from several Mendelian randomization studies which have unveiled a polygenic relationship between Lp(a) levels and BP. Furthermore, these findings harmonize with data from other basic research that associate Lp(a) levels with oxidative stress, inflammation and atherosclerotic vascular damage 35 , 36 . Despite this, clinical understanding of the Lp(a)-BP relationship, especially during night-time, remains somewhat underexplored.…”

Section: Discussionsupporting

confidence: 86%

Assessing the relationship between lipoprotein(a) levels and blood pressure among hypertensive patients beyond conventional measures. An observational study

Vazquez-Agra,

Cruces-Sande,

Barbosa-Gouveia

et al. 2024

Sci Rep

View full text Add to dashboard Cite

High lipoprotein(a) (Lp(a)) levels are associated with an increased risk of arterial hypertension (AHT) and atherosclerotic cardiovascular disease. However, little is known about the detailed profile of AHT based on Lp(a) levels. This observational study focused on elucidating the relationship between Lp(a) concentrations and specific indices obtained from 24-h ambulatory blood pressure (BP) monitoring in hypertensive patients over 18 years of age. We gathered and analyzed data on BP indices along with demographic, epidemiological, clinical, and laboratory variables from 227 hypertensive patients, median age 56 years, including 127 women (56%). After comparing hypertensive patients with Lp(a) levels above and below 125 nmol/L, we found that a 10 mmHg increase in nocturnal systolic BP and all pulse pressure indices (24-h, daytime, and night-time) was associated with an increased risk of high Lp(a) levels by more than 20% and 40%, respectively. Similarly, each 10% increase in the area under the function over time of nocturnal diastolic BP dipping was associated with more than a 30% decrease in the odds of belonging to the elevated Lp(a) levels category. Additionally, Lp(a) levels above 125 nmol/L were associated with higher 24-h, daytime, and night-time systolic BP and pulse pressure load. The relationship between Lp(a) and AHT appears to extend beyond conventional BP measurements, which may be relevant given the prognostic implications of nocturnal BP and pulse pressure indices.

show abstract

Section: Discussionsupporting

confidence: 86%

Assessing the relationship between lipoprotein(a) levels and blood pressure among hypertensive patients beyond conventional measures. An observational study

Vazquez-Agra,

Cruces-Sande,

Barbosa-Gouveia

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Small isoforms of Lp(a) are linked to elevated serum Lp(a) levels, and thus, to an increased risk of coronary artery disease. Thus, screening for genetic factors of Lp(a) is expected to have added value and proves to be cost-effective in primary prevention, whereas the monitoring of serum Lp(a) levels could improve the prediction of the clinical risk of atherosclerotic damage in patients with ASCVD [36,37]. The five plasminogen kringle domains are numbered from 1 to 5 (i.e., KI, KII, KIII, KIV, and KV).…”

Section: Fractional Clearance Ramentioning

confidence: 99%

Assessment of Apolipoprotein(a) Isoform Size Using Phenotypic and Genotypic Methods

Fogacci,

Di Micoli,

Avagimyan

et al. 2023

IJMS

View full text Add to dashboard Cite

Apolipoprotein(a) (apo(a)) is the protein component that defines lipoprotein(a) (Lp(a)) particles and is encoded by the LPA gene. The apo(a) is extremely heterogeneous in size due to the copy number variations in the kringle-IV type 2 (KIV2) domains. In this review, we aim to discuss the role of genetics in establishing Lp(a) as a risk factor for coronary heart disease (CHD) by examining a series of molecular biology techniques aimed at identifying the best strategy for a possible application in clinical research and practice, according to the current gold standard.

show abstract

Lipoprotein a: An emerging risk identifier and evolving clinical target

Cited by 2 publications

References 18 publications

Assessing the relationship between lipoprotein(a) levels and blood pressure among hypertensive patients beyond conventional measures. An observational study

Assessing the relationship between lipoprotein(a) levels and blood pressure among hypertensive patients beyond conventional measures. An observational study

Assessment of Apolipoprotein(a) Isoform Size Using Phenotypic and Genotypic Methods

Contact Info

Product

Resources

About